New combo therapy shows promise for Steroid-Resistant ITP

NCT ID NCT05438875

Completed Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed phase 3 trial tested whether adding all-trans retinoic acid (ATRA) to eltrombopag works better than eltrombopag alone for adults with immune thrombocytopenia (ITP) that did not respond to steroids. The study enrolled 96 participants and measured sustained platelet count improvement at 18 months. The goal is to find a more effective treatment option for this chronic bleeding disorder.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: all-trans retinoic acid (ATRA) and eltrombopag
What this could lead to: If successful, this combination could offer a more effective treatment option for people with immune thrombocytopenia (ITP) that does not respond to steroids, helping maintain safe platelet levels.
What could go wrong: This is a relatively small phase 3 trial (96 participants), and results may not apply to all ITP patients. The combination may cause side effects, and long-term benefits are not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura Purpura, Thrombocytopenic, Idiopathic thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PURPURA, THROMBOCYTOPENIC, IDIOPATHIC

Contacts and locations

Locations

Beijing Tongren hospital

Beijing, Beijing Municipality, China
Department of Hematology, Beijing Friendship Hospital, Capital Medical University

Beijing, China
Department of Hematology, Beijing Hospital

Beijing, China
Department of Hematology, Senior Department of Hematology, the Fifth Medical Center of PLA General Hospital

Beijing, China
Peking University Insititute of Hematology, Peking University People's Hospital

Beijing, Beijing Municipality, 100010, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.